Rick Simpson Oil (RSO) in Crittenden County: The Complete Guide to OilWell Cannabis’ Multi-Cannabinoid Formula, Legal Access, and Evidence-Based Use

Here in Crittenden County, where the Ohio River shapes our southern border and the rolling hills of western Kentucky define our landscape, we understand what it means to look for real solutions when conventional medicine falls short. Whether you’re in Marion, the county seat where generations have farmed these fertile river bottoms, or out in Crayne, Tolu, or any of our unincorporated communities, you’ve likely seen neighbors struggle with chronic pain, cancer, sleep disorders, or the lasting scars of trauma and addiction. You’ve probably watched friends cycle through prescriptions that don’t work or cause more problems than they solve. You may have wondered if there’s something more honest, more natural, more grounded in real science than the options being pushed by distant pharmaceutical companies.

We built OilWell Cannabis for people exactly like you. We are not a faceless corporation. We’re a Houston-based company founded by Colin Valencia, a man who grew up in the tough McAllen-Reynosa border region, who learned the cannabis plant from the ground up, and who watched his beloved dog Bentley walk again after a veterinarian said euthanasia was the only option. That moment — when cannabis medicine did what pharmaceuticals could not — became the foundation of everything we do. When we say we understand suffering, desperation, and the need for alternatives, we mean it. We’ve lived it.

This guide is our complete, transparent, no-hype introduction to Rick Simpson Oil (RSO) for residents of Crittenden County. We’ll explain the history, the science, the legal framework that makes our products accessible to you, the exact formulas we use, and the evidence behind every ingredient. We’ll show you how our approach differs from traditional RSO, why that matters for your health and safety, and how you can use these formulations responsibly. We’ll cover everything from the 60-gram protocol that made RSO famous to the modern, seven-cannabinoid, terpene-rich formula we’ve refined over a decade of real-world use. And we’ll do it with the same honesty that earned us seven features on ABC13 Houston — America’s fourth-largest market — where reporters from Tom Abrahams to Nick Natario turned to Colin as the expert voice on cannabis law, medicine, and community impact.

Let’s start at the beginning, right here in Kentucky context.

Understanding Rick Simpson Oil: The History Every Crittenden County Resident Should Know

Who Was Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, a scientist, or a medical researcher. He was a power engineer and maintenance worker — a blue-collar tradesman, much like many folks here in Crittenden County who work with their hands and understand practical problem-solving. His journey into cannabis began not with a lab coat but with a workplace injury that left him with persistent tinnitus and post-concussion symptoms after falling from scaffolding in 1997. The medications doctors prescribed either didn’t help or made things worse. When he asked his physician about cannabis, he was refused.

That frustration — the feeling that the medical system has failed you and won’t consider alternatives — resonates deeply in our part of Kentucky. We’ve seen the opioid crisis devastate families from Repton to Shady Grove. We’ve watched veterans return from service with PTSD, only to be handed pills that create new problems. Simpson’s story is the story of millions of Americans who reached for cannabis when institutional medicine fell short.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia that reported THC slowing tumors in mice. That study, intended to demonstrate harm, became his reference point — even though its findings were never replicated in controlled human cancer trials.

The 2003 Moment That Started Everything

In 2003, Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Instead of pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. Important context: This is Simpson’s personal testimony. No independent medical verification, biopsy confirmation, or clinical follow-up has ever been published in any peer-reviewed source. While this event cannot be evaluated as medical evidence, it is historically significant as the catalyst for a global movement.

The Crusade: Spreading the Oil Across Borders

After 2003, Simpson committed himself to producing and distributing concentrated cannabis oil — for free. He charged nothing. He claimed to help people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more. His story spread globally through the 2005 documentary Run From The Cure, which became foundational in cannabis communities worldwide.

But his advocacy brought legal conflict. The RCMP raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Facing continued pressure, he left Canada for Europe. In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his platform.

Throughout his career, Simpson maintained that RSO could cure cancer and that pharmaceutical companies and government agencies were suppressing this knowledge. Important context: This conspiratorial framing is noted without endorsement. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance, but it is not a scientific position.

Traditional RSO Protocol: The 60-Gram, 90-Day Regimen

Simpson’s protocol was designed to deliver 60 grams of concentrated oil over approximately 90 days. Here’s exactly what he recommended:

• Week 1: Half a grain of rice-sized dose (10-15 mg) three times daily (total ~30-45 mg/day)
• Weeks 2-5: Double the dose every four days until reaching 1 gram (1,000 mg) per day, divided into three doses
• Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed
• Administration: Primarily sublingual or oral; topical for skin lesions; inhalation only for immediate symptom relief
• Tolerance: Simpson claimed patients develop tolerance to psychoactive effects within 3-4 weeks
• Post-protocol: Maintenance dose of 1-2 grams per month indefinitely

Important context for evaluating this protocol:

• No controlled trial validation exists
• Traditional RSO was crude, unstandardized material with variable potency
• Peak dosing delivers ~600-900 mg of delta-9 THC daily — far exceeding any studied clinical dose (dronabinol is typically 2.5-20 mg/day)
• Real risks at these doses include severe intoxication, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15]
• Patients with active cancer are medically complex; delaying proven therapies for unproven alternatives carries genuine harm potential

Simpson was not a scientist. He never conducted a clinical trial. His evidence was personal experience and testimonials. While he drew attention to cannabinoids as a serious research area, his cure claims exceeded the evidence then and now.

Traditional RSO vs. Modern OilWell Formulation

Traditional RSO was defined by Simpson’s method, not lab standards:

Dimension	Traditional RSO	OilWell RSO
Source material	Single high-THC indica strain, uncontrolled	Multi-cannabinoid blend from multiple sources
Extraction solvent	Naphtha or isopropyl alcohol (toxic, non-food-grade)	Modern food-grade ethanol or CO₂ (solvent-free final product)
Cannabinoid profile	THC-dominant (60-90% estimated), uncontrolled, unmeasured	Seven defined cannabinoids at specific ratios, lab-tested
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not performed	Full panel: potency, terpenes, pesticides, heavy metals, residual solvents, microbial
Residual solvents	Significant risk with naphtha	Controlled and tested; no solvents in final product
Dosing precision	Approximate, syringe-based	Measured per mL with graduated dropper (0.1 mL increments)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	Fully decarboxylated by heat	THCa included as separate ingredient at 1,500 mg
Delta-9 THC exposure	~600-900 mg/day at peak	90 mg total in entire bottle (3 mg/mL)
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

The OilWell Story: From Bentley’s Ball to Your Medicine Cabinet

Bentley’s Miracle: Where It All Began

OilWell Cannabis didn’t start in a corporate boardroom. It started with a dog named Bentley. Colin’s companion was paralyzed, facing euthanasia. Veterinarians said the pain medications would destroy his organs. The only humane option was to end his suffering.

Colin refused. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That question changed everything.

Colin created a CBD golden paste — turmeric, coconut oil, black pepper, CBD oil — and gave it to Bentley. The result was not a placebo. Dogs don’t respond to placebo. Bentley got up, walked across the room, and brought Colin his ball to play. From paralyzed to playing fetch. Bentley lived another ten years, dying naturally at age twenty.

During those ten years, Colin developed formulas for every age-related condition Bentley faced:

• Neurodegeneration → CBG neuroprotection, THCa PPARγ agonism for brain cell protection
• Dementia → CBC’s role in neurogenesis
• Glaucoma → THC’s CB1 agonism for intraocular pressure reduction
• Arthritis → Multi-pathway anti-inflammatory using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Precision mattered — Bentley’s life depended on formula accuracy.

Colin’s Personal Battle: PTSD, Benzo Addiction, and Peace

Colin also knows pharmaceutical dependence personally. He struggled with severe PTSD and benzodiazepine addiction. When he decided to quit Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge he’d built keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Doctors Use Our Formulas

Over time, the therapeutic benefits Colin discovered through Bentley became the core of his work. He has developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. The focus has always been on making cannabis accessible and effective for everyone — including vegans, diabetics, and those with specific dietary or health needs.

ABC13 Houston: Seven Features, Four Years, One Voice

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments. Five different reporters — Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff — sought Colin out across those years. No other Houston cannabis operator appears with that frequency or breadth.

The features span:

• September 2019: Texas CBD businesses booming; Colin’s foundational quote: “I’m not trying to sell people snake oil… I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

• March 2021: National decriminalization push; Colin’s insight: “Pain comes in a lot of different forms.”

• May 2021: Delta-8 THC investigation; Colin’s radical honesty: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.” This segment balanced Colin’s stance with medical caution from Dr. Michael Weaver and regulatory advocacy from Heather Fazio.

• August 2021: COVID vaccine giveaway — $35,000 in product (1,000 caviar pre-rolls) donated to encourage vaccination, coordinated with the city of Houston, no political agenda.

• October 2021: Texas Delta-8 ban; Colin proactively removed all products before enforcement and warned other operators who were unknowingly shipping Schedule I narcotics.

• October 2022: Biden marijuana pardon; Colin revealed personal marijuana conviction history: “You face challenges with housing, loans, and banking… I would love to see people not get hurt for this anymore.”

• April 2023: Texas marijuana industry creative adaptation; Colin’s “Renaissance” framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

What the media record reveals: Consistency across years, breadth of expertise, documented community action, personal stakes that transform every quote, and evolution of language reflecting industry leadership. This recognition cannot be purchased — it can only be earned.

Current Operations: Real Business, Real Trust

OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Since 2019, we’ve generated approximately $1 million in annual revenue, maintained a near-5.0 Google rating, and hold a Texas DSHS license. All artwork, formulations, and packaging are created in-house in Houston. We bring Houston grit and McAllen roots to everything we do, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy: Four Core Principles for Crittenden County

1. Accessibility Over Gatekeeping

No medical card required. Age 21+ only. Anyone in Crittenden County can purchase. We ship nationwide and internationally to customers who verify local legality.

This matters in Kentucky. While our state has a limited medical cannabis program, accessing it requires qualifying conditions, physician registration, and significant bureaucracy. For a veteran in Fredonia dealing with PTSD, a cancer patient in Mattoon navigating treatment options, or a chronic pain sufferer in Dycusburg who can’t get a medical card, our Farm Bill-compliant products provide legal access without those barriers. Rick Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

2. Patient-Controlled Potency

Traditional RSO was always fully psychoactive — high heat converted all THCa to delta-9 THC. You had no choice.

Our sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form. You decide:

• Raw (no heat): All 1,500 mg stays as THCa — completely non-psychoactive. Use this for daytime anti-inflammatory support without impairment. Perfect for working in the fields, driving, parenting, or any situation where you need to function clearly.

• Fully activated (home decarboxylation): Heat at 260°F for 45-60 minutes converts 1,500 mg THCa → ~1,315 mg delta-9 THC. Combined with the existing 90 mg delta-9 THC, you get ~1,405 mg total delta-9 THC. Combined with 6,000 mg delta-8 THC, this delivers psychoactive potency comparable to traditional illegal RSO — 100% legally, because activation occurs after purchase.

• Vape (instant decarboxylation): Our vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff.

The conversion math: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation (reflecting loss of CO₂).

Rick Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry, not rhetoric.

3. Open-Source Formulas

We publish our complete formulas publicly. Every cannabinoid, every milligram, every percentage — all detailed later in this guide. If you can’t afford our products ($129.99 for sublingual oil, $49.99 for vape cartridge), you can source the individual distillates and make your own version.

This is a direct echo of Rick Simpson’s original ethos. He gave his oil away for free and taught people to make it. He never patented his method. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

We also publish the CBD golden paste recipe that saved Bentley — so any Crittenden County pet owner facing a similar crisis can make it today:

CBD Golden Paste for Pets (Original Open-Source Formula)

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup unrefined organic coconut oil
• 1-2 tsp freshly ground black pepper (critical for absorption)
• CBD oil (dosage depends on pet size; consult veterinarian)

Mix turmeric and water over low heat until thick paste forms (7-10 minutes). Add coconut oil and pepper. Cool, store in refrigerator up to two weeks. Mix with pet’s food once or twice daily.

4. Evidence-Informed, Not Evidence-Overstating

Rick Simpson operated without access to peer-reviewed literature. We have that access, and we use it to distinguish between what is well-supported, what is emerging, and what is overstated.

The GENERAL KNOWLEDGE section of this document (which we’ll detail below) applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews, then institutional summaries, then preclinical literature. Every compound-level claim is tied to specific peer-reviewed sources. We don’t exempt ourselves from these standards. When we cite evidence for a cannabinoid or terpene, we’re showing you exactly what the science says — and what it doesn’t.

Farm Bill Compliance and THCa Legal Framework: How Crittenden County Residents Can Access This Legally

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle — 3 mg per mL — well under the 0.3% threshold. All cannabinoids are hemp-derived. This makes the product legal under federal law and in Kentucky.

THCa is the key. THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is Farm Bill compliant at point of sale because it is not delta-9 THC.

Practical significance for you in Crittenden County: You can legally purchase, possess, and transport our product. You can then activate it at home through heating, converting THCa to delta-9 THC at your discretion. This is the most significant legal cannabis access innovation in history — backed by actual chemistry, not loopholes.

Important legal notice: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Kentucky laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Complete Product Specifications: What Crittenden County Residents Are Buying

RSO Sublingual Oil — $129.99

Component	Amount	Evidence-Based Role
CBD	4,500 mg	Strongest human evidence for seizure disorders, promising for anxiety and pain [1]-[6]
CBG	3,000 mg	Neuroprotective potential, anti-inflammatory; emerging evidence [7][8]
Delta-8 THC	6,000 mg	Psychoactive THC analogue; real pharmacologic activity with less robust safety data than delta-9 [9]-[11]
THCa	1,500 mg	Non-psychoactive precursor; anti-inflammatory via COX-2, neuroprotective via PPARγ [12]
Delta-9 THC	90 mg	Established therapeutic relevance for nausea, appetite, pain; clear intoxication and safety liabilities [1][13]-[15]
CBN	750 mg	Marketed for sleep but weak human evidence; clinical support remains limited [16][17]
CBC	750 mg	Distinct pharmacodynamics; antinociceptive, antibacterial, anti-seizure potential; clinically immature [18][19]
Total Cannabinoids	16,590 mg	553 mg per mL

Additional specs:

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: Organic MCT oil
• Format: 30 mL bottle with graduated dropper (0.1 mL increments)
• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Doses per bottle: ~40-60 depending on serving size

RSO Vape Cartridge — $49.99

Component	Percentage	Converted mg (1g cart)
CBD	30%	~300 mg
CBG	20%	~200 mg
Delta-8 THC	15%	~150 mg
THCa	10%	~100 mg (auto-converts to ~88 mg delta-9 THC when vaped)
CBN	10%	~100 mg
CBC	10%	~100 mg
Total Cannabinoids	95%	900+ mg

Additional specs:

• Live Terpenes: 5%+
• Format: 1-gram 510-thread cartridge (universal battery compatibility)
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (dependent on inhalation technique)
• Auto-decarboxylation: THCa converts instantly to delta-9 THC at vaping temperature (400-450°F)

When to Use Each Format: A Crittenden County User’s Guide

Your Need	Best Format	Why It Works for You
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset; perfect for breakthrough moments
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration; steady support through the night
Maximum absorption	Sublingual	13-19% bioavailability; more cannabinoids reach your system
Portability/discretion	Vape	Compact; no measuring; use anywhere in Crittenden County
Precise dosing	Sublingual	Graduated dropper lets you adjust by 0.1 mL increments
Daytime, non-psychoactive	Sublingual (raw)	THCa stays inactive; zero impairment; work in fields, drive safely
Nighttime, full potency	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for strong therapeutic effect

Evidence Deep Dive: What the Science Actually Says

Research Method: How We Evaluate Evidence

We prioritize sources in this order: human clinical evidence, systematic reviews/meta-analyses, NIH/institutional summaries, then preclinical literature when human data are sparse. This matters because the evidence base is not evenly distributed. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, and early translational studies.

Institutional Baseline: What NIH and FDA Say

• NCCIH states strongest established evidence is for rare epilepsies (CBD), chemotherapy nausea/vomiting (THC), and HIV/AIDS appetite (THC). Only modest evidence for chronic pain and MS symptoms. Many other uses remain early-stage [1].
• FDA has not approved cannabis plant itself for medical use; only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol, nabilone) have specific approvals [1].
• Safety concerns highlighted by NIH: impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination/labeling inaccuracy, THC-vape lung injury [1].

Cannabinoid-by-Cannabinoid Evidence

CBD (4,500 mg in our formula)

• Strongest evidence: Purified CBD for seizure disorders (Epidiolex) [1][2]
• Anxiety: 2024 meta-analysis shows significant anxiolytic signal but limited clinical samples; more trials needed [3]
• Pain: 2024 review concludes promising but heterogeneous; trial quality limits confidence [4]
• Sleep: 2023 review finds literature methodologically weak; few objective sleep assessments [5]
• Safety: 2023 meta-analysis finds real signal for liver enzyme elevation and possible drug-induced liver injury, especially with concentrated oral products and polypharmacy [6]. NCCIH flags diarrhea, sleepiness, appetite change, mood effects, liver abnormalities, drug interactions [1]
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications, not broad wellness claims

CBG (3,000 mg)

• Evidence profile: Mostly review/preclinical; human evidence sparse [7][8]
• Pharmacology: Biosynthetic precursor; interacts with cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling; mechanistically interesting but not clinically established [7]
• Research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity; primarily pharmacology-led hypotheses/preclinical [7][8]
• Caution: 2021 review notes CBG sold commercially while evidence base remains thin; claims outrun science [7]
• Bottom line: Promising minor cannabinoid with limited clinical validation

Delta-8 THC (6,000 mg)

• Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 [9]-[11]
• Comparative pharmacology: 2022 review shows delta-8 and delta-9 have broadly similar PK/PD; delta-8 is partial CB1 agonist, less potent due to weaker CB1 affinity [9]
• Public health literature: 2023 scoping review found evidence dominated by animal studies, product chemistry, use reports; noted adverse consequences and regulatory concerns [10]
• Manufacturing: 2024 chemistry review notes commercial interest tied to greater stability and easier synthesis relative to naturally scarce plant levels; product-byproduct and lab-testing questions matter [11]
• Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, manufacturing-quality uncertainty

THCa (1,500 mg)

• Evidence profile: Important chemically/formulation-wise, low direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC; may represent large share of THC-related content in raw plant material. Decarboxylates to THC during heating/storage/processing [12]
• Psychoactivity: Does not produce psychoactive effects associated with THC IF molecule stays acidic and is not substantially decarboxylated [12]
• Research status: In vitro/rodent literature suggests anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities; not equivalent to established human outcomes [12]
• Bottom line: Highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, storage. Any claim must account for possible conversion to THC

Delta-9 THC (90 mg)

• Evidence profile: Strongest human evidence of psychoactive cannabinoids listed; clearest adverse-effect burden [1][13]-[15]
• Institutionally best supported: NCCIH identifies chemotherapy nausea/vomiting, HIV/AIDS appetite, some MS/pain outcomes; many other uses uncertain/early-stage [1]
• Pain evidence: 2022 systematic review found high-THC or balanced THC:CBD products may provide short-term pain benefit but increase dizziness, sedation, nausea, discontinuation [13]
• Pharmacokinetics: Inhaled THC: seconds to minutes onset, peaks 15-30 min, lasts few hours. Oral THC: later onset, later peak, longer duration; matters for benefit and overconsumption risk [14]
• Mental health risk: 2025 systematic review found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder; concerning signals for anxiety/depression in nontherapeutic settings [15]
• Broader safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency, withdrawal, pregnancy concerns, accidental pediatric exposure, vape lung injury [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but clearest intoxication, psychiatric, and dose-related safety liabilities

CBN (750 mg)

• Evidence profile: Weak human evidence; marketing moved ahead of data [12][16][17]
• What it’s marketed for: Sleep and sedation. Clinical support far thinner than market suggests [16][17]
• Best review for sleep claim: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles; found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated review concluded overall cannabinoid sleep research doesn’t match real-world use scale; need for better-designed, adequately powered trials remains substantial [17]
• Chemical context: THC can degrade toward CBN under certain conditions (aging/oxidation), which helps explain why CBN discussed in those contexts [12]
• Bottom line: Clearest example where cultural reputation stronger than current clinical evidence base

CBC (750 mg)

• Evidence profile: Emerging, intriguing, overwhelmingly preclinical/review-based [18][19]
• Pharmacology/therapeutic interest: 2024 focused review argues CBC has distinct PK/PD and receptor behavior; highlights antinociceptive, antibacterial, anti-seizure as especially interesting research targets [18]
• Older literature: Anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesia, possible neurobiological/antiproliferative relevance; not yet strong patient-facing evidence [19]
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active

Terpene-by-Terpene Evidence

Limonene (citrus-bright)

• Evidence profile: Largely review/preclinical, useful safety literature [20]-[22]
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities; overwhelming share from nonhuman/non-cannabis literature [21]
• Safety note: Limonene oxidation products (hydroperoxides) are clinically relevant contact allergens in patch-testing literature [22]
• Bottom line: Biologically active, widely discussed, but cannabis-specific therapeutic claims should stay conservative

Myrcene

• Evidence profile: Mostly preclinical, very limited human evidence [20][23]
• Research summary: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, possible mechanisms; explicitly states human studies lacking [23]
• Interpretation caution: Often invoked as proven human sedative explaining couch-lock; stronger claim than human evidence supports [20][23]
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood/pain/sedation remain far ahead of definitive human proof

Caryophyllene (β-caryophyllene – pepper/spice)

• Evidence profile: Among most mechanistically interesting terpenes due to direct cannabinoid-system relevance; still mostly preclinical [24]
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist — unusual, makes it especially relevant pharmacologically rather than purely aromatic [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective; human clinical confirmation limited [24]
• Bottom line: Arguably strongest candidate terpene with cannabinoid-system significance, but should not be described as clinically proven for outcomes commonly attributed

Pinene (forest-fresh)

• Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25]
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study; emphasized lack of well-designed clinical trials [25]
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC cognitive effects remain interesting hypotheses, not settled facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory

Linalool (floral, lavender)

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research summary: Repeatedly discussed for stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation while emphasizing lack of robust human trials [25]
• Additional literature: Possible antidepressant mechanisms, neuropharmacologic relevance; translational rather than definitive clinical story [26]
• Safety note: Oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22]
• Bottom line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises

Humulene (earthy, woody)

• Evidence profile: Translationally interesting, still early [20][27]
• Scoping-review findings: 2024 review analyzed 340 articles; found broad preclinical evidence for anti-inflammatory/biologic effects; some rodent work suggested cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Findings valuable for hypothesis generation, don’t yet establish consistent human efficacy across pain/inflammation/mood outcomes [27]
• Bottom line: One of more interesting terpene research targets, but remains far from clinically settled

Terpinolene (piney, fruity, sparkling)

• Evidence profile: Among least clinically characterized terpenes in this file [20][28]
• Systematic-review findings: 2021 review screened 2,449 records, included 57 studies; concluded terpinolene has range of reported biological effects but evidence base dominated by in silico, in vitro, animal studies rather than human trials [28]
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20]
• Bottom line: Biologically interesting, but especially underdeveloped clinically

Research Limits and Interpretation Rules

1. Evidence is highly uneven. CBD and delta-9 THC support most detailed human-facing statements; the rest require more caution.
2. Whole-cannabis, purified-molecule, semisynthetic, and terpene-only data are NOT interchangeable. Common error: letting evidence from one category stand in for another.
3. Minor cannabinoids and terpenes are commercially interesting BECAUSE they’re underexplored. Claims often become inflated.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent PK all materially affect real-world interpretation [1][10][11][14].
5. THCa chemistry changes with storage/heating. For THCa, chemistry is destiny — processing can change actual exposure profile by converting acidic cannabinoids to neutral THC [12].

Common Overstatements to Avoid

• CBN is clinically proven sleep aid → More accurate: Specific sleep evidence for CBN remains weak, no strong validated-trial base yet [16][17]
• Myrcene is proven human sedative → More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for common sedating claims is limited [20][23]
• Terpenes have proven entourage effects → More accurate: Entourage hypotheses influential and worth studying, but robust clinical proof limited and highly compound-specific [20][29]
• THCa is always nonpsychoactive → More accurate: THCa itself not THC, but heating/processing can convert THCa to THC, changing effective exposure [12]
• Delta-8 THC is safe because hemp-derived → More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9, often entangled with manufacturing/testing concerns [9]-[11]

Condition-Specific Usage Context for Crittenden County Residents

Important Disclaimer: These contexts are informed by cannabinoid research cited above and our formulation rationale. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT substitutes for professional medical care. These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

For Crittenden County cancer patients traveling to treatment centers in Paducah, Evansville, or Nashville:

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence context: Delta-8 antiemetic evidence [9], delta-9 nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

Local resource note: If you’re receiving treatment at Baptist Health Paducah or Deaconess Midtown Hospital, coordinate with your oncology team. Our products are complementary support, not replacements for proven therapies.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

For those in Crittenden County dealing with pain from agricultural work, aging, or injury:

• Daytime: 0.3-0.5 mL raw sublingual — anti-inflammatory cannabinoid exposure without psychoactive impairment. Keep working the land, driving, functioning.
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Local context: If you’re part of the Crittenden County agricultural community dealing with chronic back pain from decades of farming, or if you’re a veteran with service-related injuries, this multi-pathway approach targets inflammation through several receptor systems simultaneously — something single-cannabinoid products cannot do.

Sleep Support

For the many Crittenden County residents struggling with insomnia:

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN — dosage level investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN — above 20 mg threshold associated with reduced sleep disturbance in published research

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature [17]

Important note: While CBN is marketed heavily for sleep, the clinical evidence remains weaker than marketing suggests. Results vary. Some find CBN helpful; others don’t. Our formula includes it as part of multi-cannabinoid synergy, not as a standalone sleep miracle.

Anxiety and Stress

For those in Crittenden County facing the pressures of rural life, economic uncertainty, or family stress:

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

Local relevance: If you’re in Marion dealing with small-town economic pressures, or in Crayne facing isolation, this approach provides functional relief without the “high” that interferes with daily responsibilities.

General Titration Principle for Crittenden County Residents

Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary by body weight, metabolism, tolerance, concurrent medications, and other factors.

If you’re new to cannabinoids: Start with raw sublingual (non-psychoactive) for several days to assess tolerance and effects before considering decarboxylation.

If you’re an experienced user: You may find the graduated dropper allows precise titration to your desired effect level.

Delivery and Global Accessibility: How Crittenden County Gets OilWell Products

Nationwide and International Shipping to Kentucky

We offer shipping to all 50 states where Farm Bill-compliant products are legal, including Kentucky. For Crittenden County residents:

• USPS Priority Mail: 2-3 business days to Marion, Fredonia, or any address in the county
• FedEx/UPS Ground: 3-5 business days
• Discreet packaging: No cannabis branding visible on exterior
• Tracking provided: Monitor your order from our Houston facility to your doorstep
• Temperature-stable packaging: Ensures product integrity during Kentucky summers
• Signature-required option: Available for added security

Every package includes full documentation, Certificate of Analysis (COA), and receipt for your records.

International Shipping

Crittenden County residents with family overseas should know: Our THCa legal framework enables international shipping to jurisdictions with compatible hemp laws. Customers accept all customs and legal responsibility, but the product is shippable because it contains <0.3% delta-9 THC at point of sale.

Why This Matters: From Illegal Underground to Legal Access

Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the UK can now access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. We’ve completed a piece of Simpson’s vision that prohibition made impossible.

How to Order and Contact Us

Order online: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Phone: (832) 416-2816

Email: [email protected]

Address: 810 Richmond Avenue, Houston, TX 77006 (Montrose neighborhood)

Business hours:

• Monday-Thursday: 10:00 AM – 7:00 PM
• Friday-Saturday: 10:00 AM – 10:00 PM
• Sunday: 10:00 AM – 4:00 PM

For Crittenden County residents with questions about dosing, interactions, or condition-specific use, call us. Colin and our team answer directly. No corporate runaround.

Safety, Warnings, and Disclaimers

FDA Disclaimer: These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

Age requirement: 21+ only

Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Consult your healthcare provider before use if you have a medical condition, take medications, are pregnant or nursing, or have health concerns.

Keep out of reach of children. Accidental pediatric exposure is a serious risk.

Drug interactions: CBD and other cannabinoids can interact with many medications, including blood thinners, anti-seizure drugs, and certain antidepressants. The 2023 systematic review on CBD-associated hepatotoxicity found real signals for liver enzyme elevation, especially relevant for concentrated oral products and polypharmacy settings [6].

Pregnancy: NIH warns against cannabis use during pregnancy due to potential impacts on fetal development.

Mental health: High-concentration THC products have consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder [15]. If you have a history of psychotic disorders, use extreme caution or avoid psychoactive cannabinoids.

Quality assurance: We test every batch for potency (±2% accuracy), heavy metals (arsenic, cadmium, lead, mercury below FDA limits), pesticides (400+ compounds), residual solvents (FDA Class 3 limits <5,000 ppm), and microbial pathogens (E. coli, Salmonella, Aspergillus). COAs available on request.

Final Thoughts for Crittenden County

We built OilWell Cannabis for people who’ve been let down by the system. For the farmer in Crayne whose back pain never quits. For the veteran in Fredonia still fighting PTSD years after service. For the cancer patient in Marceline searching for options beyond what the oncologist in Paducah offered. For the parent in Marion watching a child suffer and wondering if there’s something more honest than another prescription.

We don’t promise miracles. We promise transparency, quality, and the best possible version of the information so you can give it a fair shot and decide if it’s right or wrong for you.

Our formulas are open-source because Rick Simpson taught us that medicine should be accessible. Our products are lab-tested because you deserve to know exactly what you’re putting in your body. Our approach is evidence-informed because hype helps no one. And our commitment is to you — the residents of Crittenden County and beyond — who deserve real solutions grounded in real science.

Order today: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Or call us: (832) 416-2816

We’ll answer directly. We’ll help you find the right product and dosing approach for your situation. And we’ll never sell you something we wouldn’t use ourselves — because Colin uses these products every day to manage his own PTSD and insomnia.

From Bentley’s ball to your medicine cabinet, this is OilWell Cannabis. This is what real RSO looks like in the modern era. And it’s now available to you in Crittenden County, Kentucky.

References

General Knowledge Section References [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

Rick Simpson Section References –

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

Final note to our Crittenden County family: We wrote this guide because you deserve the full picture. No secrets. No hype. Just real science, real formulas, real access, and real people who understand what you’re going through. Whether you’re in Marion, Dycusburg, Fredonia, or anywhere else in our corner of Kentucky, we’re here for you.

Order now: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Call us: (832) 416-2816

Our promise: The same integrity, creativity, and commitment that defined us from the day Bentley got up and brought his ball to play. That’s OilWell Cannabis. That’s what we bring to Crittenden County.